Miranim Bio is developing a first-in-class RNA interference (RNAi) therapeutic that precisely silences a disease-driving liver protein previously considered undruggable by small molecules. Targeting metabolic dysfunction-associated steatotic liver disease (MASLD/MASH), the platform leverages two decades of mechanistic metabolic research and has potential expansion into type-2 diabetes. The liver-directed approach aims to improve metabolic liver pathology and address insulin resistance, offering a differentiated mechanism for pharmaceutical partners.
- Biotechnology
- Drug Discovery & Therapeutics
- Healthcare Technology
Funding
Funding not disclosed
Founders
Product
Problem
Metabolic dysfunction-associated steatotic liver disease (MASLD/MASH) represents a growing global health burden, yet a key disease-driving liver protein has proven practically undruggable through traditional small molecule approaches. This leaves a significant therapeutic gap for patients with progressive liver pathology and related metabolic complications such as insulin resistance.
Solution
Miranim Bio is developing a first-in-class, liver-directed RNA interference (RNAi) therapeutic that silences disease-driven proteins directly in the liver, bypassing the limitations of conventional small molecule druggability. The approach builds on 20 years of mechanistic metabolic research and directly targets the site of disease—the liver—to improve metabolic liver pathology and address insulin resistance. The platform offers a differentiated mechanism in a crowded MASLD/MASH field and holds potential expansion into type-2 diabetes, providing pharmaceutical partners both innovation and pipeline diversification. The therapeutic is designed to offer strong academic validation and translational rationale for advancing into clinical development.
Target Audience
Primary partners are pharmaceutical and biotech companies seeking novel metabolic mechanisms and RNA-based therapeutics to expand their pipelines in MASLD/MASH and metabolic disease.
Features
- Liver-directed RNAi mechanism that silences a target protein previously considered undruggable by small molecules
- Directly targets the liver, the primary site of metabolic disease pathology
- Built on two decades of mechanistic metabolic disease research providing strong scientific validation
- Differentiated mechanism designed to improve metabolic liver pathology and address insulin resistance
- Potential expansion beyond MASLD/MASH into type-2 diabetes, offering pipeline diversification